Gainey McKenna & Egleston Files Securities Class Action Against Lantheus Holdings, Inc.
Gainey McKenna & Egleston has announced that it filed a securities class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH) in the U.S. District Court for the Southern District of New York.
The case is brought on behalf of all investors who purchased or otherwise acquired Lantheus stock between February 26, 2025, and August 5, 2025.
The lawsuit centers on claims that Lantheus misled shareholders about the competitive and pricing landscape for Pylarify, the company’s key imaging agent for prostate cancer.
According to the complaint, executives struck an optimistic tone in public statements but failed to disclose that:
-
The company wasn’t equipped to fully assess competitive pricing pressures for Pylarify.
-
A price hike rolled out in early 2025, despite evidence of price erosion the year before, left the door open for rivals to gain ground.
-
These dynamics put Pylarify’s pricing, revenue, and long-term growth at risk.
When the company revealed in early August that Pylarify sales had dropped 8.3% year-over-year and slashed its full-year outlook, the stock price tumbled almost 30% in a single trading day.
Investors who purchased Lantheus shares during the class period may have the right to join the lawsuit.
The deadline to seek appointment as lead plaintiff, the investor who acts on behalf of the class is November 10, 2025.
For more details, investors can contact:
-
Thomas J. McKenna, Esq. – tjmckenna@gme-law.com
-
Gregory M. Egleston, Esq. – gegleston@gme-law.com
-
Or call (212) 983-1300 to reach Gainey McKenna & Egleston directly.
Lantheus is a radiopharmaceutical company with a nearly 70-year legacy of innovating patient care. Headquartered in Bedford, Massachusetts, Lantheus is a leader in radiodiagnostics and is expanding aggressively into radiotherapeutics. Their journey began in 1956 as New England Nuclear and includes several landmark milestones—from FDA approvals and mergers to pioneering products like DEFINITY, AZEDRA, and PYLARIFY. Today, they partner with academic institutions and industry players to advance precision medicine and tackle unmet medical needs, with a portfolio focused on both disease detection and treatment innovation.
Gainey McKenna & Egleston is a New York and New Jersey-based civil litigation firm with nearly 30 years of legal experience. Litigating nationwide in both federal and state courts, the firm focuses on class actions for investors, consumers, and small businesses. Its core expertise spans securities fraud, ERISA, shareholder derivative, complex commercial and tort cases, as well as consumer and employment law matters like wage and hour disputes. Known for its aggressive, client-focused approach, the firm routinely handles multi-district litigation and is well-versed in the Manual for Complex Litigation and class-certification procedures.
More Articles
